Mouse Models of Lung Fibrosis

Area of Science:

• Biomedical Research
• Translational Science
• Drug Development

Background:

• Drug discovery is lengthy and expensive, with low success rates for lead candidates.
• Optimizing evaluation processes can streamline the journey from discovery to market approval.
• Fibrotic lung diseases require effective and safe therapeutic interventions.

Purpose of the Study:

• To present preclinical strategies for assessing therapeutic candidates for fibrotic lung disease.
• To describe a decision-making process for evaluating drug tolerability and efficacy.
• To highlight the value of preliminary discovery trials in selecting study outcomes.

Main Methods:

• Preclinical evaluation of therapeutic candidates.
• Decision-making framework for drug development.
• Methodologies for assessing tolerability and efficacy.
• Protocol for preliminary discovery trials.

Main Results:

• Established preclinical strategies for fibrotic lung disease drug candidates.
• Defined a decision-making process for optimizing candidate evaluation.
• Demonstrated the utility of preliminary trials in outcome selection.

Conclusions:

• The described preclinical strategies and decision-making process can guide researchers in developing fibrotic lung disease therapies.
• Implementing these protocols can aid in selecting suitable outcomes for validation studies.
• This approach aims to facilitate the development of safe and effective treatments for patients.